There is a lot of us that read this board that agree with you. I bought AMBS for Lympro which in all honestly seems to be a dud. I view the master service agreement with ICON as someone hiring a plumber not a partner with a stake in its success and it looked like most investors agree since the stock dropped from .13 cents the day it was announced down to around .07.
If it wasn't for the ESS and MS precise acquisition we would be trading at .05 cents like SOL and company was spewing months ago.
Only time will tell if this stock will begin to move forward again but until actual revenue hits or GC and the team give actual revenue guidance we will be stuck at .08
WD
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links